Global Prediabetes Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Prediabetes Market is presumed to reach the market size of nearly USD 412.08 Million by 2032 from USD 202.4 Million in 2023 with a CAGR of 8.22% under the study period 2024 - 2032.

Prediabetes is a health condition featured by elevated blood sugar levels that exceed usual but are not great enough to be classified as type 2 diabetes. Individuals with prediabetes are at a higher risk of developing diabetes, heart disease, & stroke if left untreated. Lifestyle modifications such as regular exercise, nutritious dietary habits, and weight management can help delay or prevent the progression of type 2 diabetes. Regular monitoring of blood sugar levels and screening for other risk factors are crucial for early detection and intervention.

MARKET DYNAMICS

The prediabetes market is influenced by several factors, including the rising prevalence of prediabetes, increasing awareness about diabetes prevention, and initiatives promoting early intervention and lifestyle modifications. Prediabetes poses a significant risk factor for the development of diabetes and cardiovascular diseases. With the global burden of diabetes reaching epidemic proportions, there is growing recognition of prediabetes as a critical public health concern, driving efforts to identify at-risk individuals and implement preventive measures. Moreover, awareness campaigns, community-based diabetes prevention programs, and workplace wellness initiatives raise public awareness about the importance of healthy lifestyle choices in preventing diabetes and reducing disease burden. Additionally, advancements in diagnostic technologies and risk assessment tools enable healthcare providers to identify individuals with prediabetes early and implement personalized interventions to mitigate disease progression. Furthermore, collaborations between healthcare organizations, government agencies, and non-profit organizations support the implementation of evidence-based interventions targeting prediabetes risk factors, such as obesity, sedentary lifestyle, and unhealthy diet. However, lifestyle changes leading to increased prevalence of prediabetes, rising healthcare costs, and limited access to preventive care services may impede market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of prediabetes. The growth and trends of prediabetes industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the prediabetes market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Diguanide
Thiazolidinediones
Glucagon-Like Peptide-1 Agonists (GLP-1)
SGLT2 Inhibitors
DPP-4 Inhibitors
Others

By Age Group

Children (12-18 Years)
Adults (18-49)
Elderly (50+)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prediabetes market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prediabetes market include Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, Bristol-Myers Squibb. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114025

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PREDIABETES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Diguanide Historic and Forecast Sales by Regions
5.5 Thiazolidinediones Historic and Forecast Sales by Regions
5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
6.5 Adults (18-49) Historic and Forecast Sales by Regions
6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

8.1. Prediabetes Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novo Nordisk
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Valbiotis
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Resverlogix
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Caelus Health
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. SciMar
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Boston Therapeutics
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Aphaia Pharma
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. AstraZeneca
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bristol-Myers Squibb
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies